TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03811054
Drug: Apatinib（250mg/d） combined with EGFR-TKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with advanced non-small cell lung cancer (NSCLC) who had treated with EGFR-TKI and progressed slowly because of resistance are underwent with apatinib mesylate and continuous EGFR-TKI.
Study: NCT04519762
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study: NCT04519762
Drug: Inotropes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of severe sepsis/septic shock via fluid therapy, antibiotics, vasopressors and inotropics.
Study: NCT05307718
Drug: Oral Anticoagulant, Direct-Acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly indicated indication for use: DOAC; platelet aggregation inhibitors from the P2Y12 receptor antagonist group; and HMG-CoA reductase inhibitors (statins); as monotherapy or without restriction with respect to any other concomitant pharmacotherapy. Subjects will be followed up during regular visits.
Study: NCT00369161
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02782754
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02347072
Drug: Spiriva® Respimat® (Tiotropium Bromide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
Study: NCT03579823
Drug: AVT02 100MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: prefilled syringe at a concentration of 100MG/ML delivering 40MG of AVT02, as a single dose on day 1 day 1
Study: NCT00275015
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03973697
Drug: Penn Microbiome Therapy - 001
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fecal Microbiota for Transplant, enema product
Study: NCT03973697
Drug: Penn Microbiome Therapy - 003
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fecal Microbiota for Transplant, capsule product
Study: NCT01129271
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01404949
Drug: Tretinoin and Arsenic Trioxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description
Study: NCT03879252
Drug: Mouthwashes
Normalized name: MOUTHWASHES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwashes three times a day with a 1.4% baking mouthwash solution.
Study: NCT02741115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT00521885
Drug: Arixtra (Fondaparinox) 2.5 mg SC Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
Study: NCT00521885
Drug: Lovenox 40mg SC Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
Study: NCT01615978
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Study: NCT00033878
Drug: Noni Extract
Normalized name: noni fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01325571
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00502853
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25mg/week
Study: NCT00497055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Aripiprazole gel caps.
Study: NCT01210014
Drug: zinc sulphate 220mg/day in one dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.~The clinical data were scored according to the size of lesions were scored subjectively.~the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again.
Study: NCT01170819
Drug: Dinoprostone 10 mg controlled-release vaginal insert
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
Study: NCT02867800
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Standard of Care) Premedication~Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)
Study: NCT02867800
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Standard GVHD Prophylaxis)~Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight.
Study: NCT03171740
Drug: Oral saline
Normalized name: Walgreens Phosphate Oral Saline Laxative SF Solution (Cherry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral saline, 0.25ml/kg
Study: NCT00960973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02547701
Drug: P-3058
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00927225
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03338244
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months
Study: NCT03338244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo suspension every 6 months
Study: NCT03970200
Drug: Penn Microbiome Therapy - 001
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fecal Microbiota for Transplant, enema product
Study: NCT03970200
Drug: Penn Microbiome Therapy - 003
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fecal Microbiota for Transplant, capsule product
Study: NCT01422707
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg/m2/per day PO at bedtime (X4 weeks)
Study: NCT02548715
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02548715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01139671
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.~The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses.
Study: NCT02774187
Drug: Folfox Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin , fluorouracil, and leucovorin
Study: NCT01634568
Drug: V81444
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending oral doses of V81444 and placebo~Multiple ascending oral doses of V81444 and placebo
Study: NCT02322333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00076999
Drug: TPV oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipranavir oral solution
Study: NCT00076999
Drug: RTV oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir oral solution
Study: NCT03780972
Drug: ONL1204
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection
Study: NCT00966901
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
Study: NCT00966901
Drug: No Patch Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
Study: NCT00813436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline liquid, intranasally administered
Study: NCT01578499
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate tablets.
Study: NCT02468713
Drug: Combiflex® lipid peri
Approvals — FDA: no, EMA: no, PMDA: no
Description: total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
Study: NCT02468713
Drug: Winuf® peri
Approvals — FDA: no, EMA: no, PMDA: no
Description: total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
Study: NCT00508157
Drug: Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, According to summary of product characteristics (SmPC)
Study: NCT00614757
Drug: N-acetylcysteine 20% 4ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 20% 4ml
Study: NCT00614757
Drug: N-acetylcysteine 20% in 4 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine 20% in 4 ml
Study: NCT00073008
Drug: GW572016 (lapatinib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tyrosine kinase inhibitor
Study: NCT02350088
Drug: probiotics
Normalized name: probiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: probiotics
Study: NCT02350088
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02130700
Drug: VT-464: given orally twice daily in 28-day cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
Study: NCT03828682
Drug: Mycophenolic Acid Oral Product
Normalized name: mycophenolic acid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: mycophenolic acid tablets
Study: NCT03831269
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomly distributed and start taking azithromycin according to the known dose /kg/day for repeated cycles till improvement or reaching the end of study
Study: NCT00808470
Drug: beta-carotene, vitamins C and E, magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mint-flavored tablets per day, taken once daily~total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene.
Study: NCT02356107
Drug: 5-hydroxytryptophan and Creatine monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00555776
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo is given with the same definition as Gabapentin
Study: NCT02760121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00320697
Drug: Placebo pill + placebo patch
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
Study: NCT01583283
Drug: ACY-1215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
Study: NCT02669667
Drug: MEDI9314
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of MEDI9314
Study: NCT02669667
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of placebo
Study: NCT04399538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT00840034
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose is 6 milligrams (mg), then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered orally (PO), once daily (QD) for up to 10 weeks followed by a 2 week taper.
Study: NCT00840034
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 tablets PO QD for up to 12 weeks
Study: NCT04671056
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGL-3196 100 mg tablet administered orally in the morning for 13 days
Study: NCT01777737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical capsules to cotrimoxazole
Study: NCT01941537
Drug: ILV-094
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of ILV-094
Study: NCT01941537
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
Study: NCT04798326
Drug: Xgeva®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects would receive a single 120mg (1.7 mL) of Xgeva® through subcutaneous injection, on the first day of treatment.
Study: NCT04091945
Drug: LT3001 Drug Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active comparator
Study: NCT04091945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT02552953
Drug: CYC065
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02419651
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive 100 mg diclofenac 1 hour before the procedure
Study: NCT02419651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive a placebo 1 hour before the procedure
Study: NCT01482299
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 (everolimus) 10 mg daily, orally without interruption.~1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability.
Study: NCT02474355
Drug: AZD9291 Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
Study: NCT00298363
Drug: ETV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match ETV QD
Study: NCT00846690
Drug: benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20% benzocaine., topical placement onto site, minimal amount, for 1 minute
Study: NCT01198535
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02263729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01928199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00315718
Drug: Extract from Hintonia latiflora bark
Normalized name: quebracho bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00755261
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
Study: NCT05672680
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo equivalent
Study: NCT03959488
Drug: MEDI8897
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-RSV monoclonal antibody with an extended half-life
Study: NCT01026818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by mouth, daily or on demand for 9 months
Study: NCT00571116
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01982799
Drug: oral naproxen
Normalized name: naproxen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: naproxen
Study: NCT00575471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets once daily for 12 weeks
Study: NCT02932605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04575584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study: NCT02085070
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV MK-3475
Study: NCT04511000
Drug: Lipilou®(generic atorvastatin drug) 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to experimental group are treated with Lipilou® 20 mg
Study: NCT04511000
Drug: Lipilou®(generic atorvastatin drug) 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to comparator group are treated with Lipilou® 10 mg
Study: NCT02653898
Drug: DHA-PIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
Study: NCT00004197
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004197
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04293172
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the open-label Run-in period (patients aged 6 to \<24 months only) will receive ticagrelor 5 mg twice a day (body weight 6 to ≤9 kg), 10 mg twice a day (body weight \>9 to ≤12 kg) or 15 mg twice a day (body weight \>12 to ≤24 kg) for 14 days.~The double-blind IP will be based on 5 weight bands:~* 6 to ≤9 kg: ticagrelor 5 mg or matching placebo, twice a day~* \>9 to ≤12 kg: ticagrelor 10 mg or matching placebo, twice a day~* \>12 to ≤24 kg: ticagrelor 15 mg or matching placebo, twice a day~* \>24 to ≤48 kg: ticagrelor 30 mg or matching placebo, twice a day~* \>48 kg: ticagrelor 45 mg or matching placebo, twice a day
Study: NCT00715520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.~The order in which Placebo is given will be randomized per participant.
Study: NCT01378715
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
Study: NCT02072070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control(Normal Saline)
Study: NCT01962246
Drug: Oxaliplatin; Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
Study: NCT00496587
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m\^2 By Mouth Twice Daily On Days 1-21.
Study: NCT01937884
Drug: Parenteral Nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004088
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03564132
Drug: Yigansan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yigansan granules
Study: NCT03564132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-tenth concentration of Yigansan manufactured to mimic Yigansan granules
Study: NCT02806830
Drug: Optive
Normalized name: optive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
Study: NCT03706469
Drug: TAK-831 T2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-831 T2 Tablets.
Study: NCT00332774
Drug: Nepafenac ophthalmic solution 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop 4 times daily for 90 days
Study: NCT00332774
Drug: Ketorolac Tromethamine ophthalmic solution 0.4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop 4 times daily for 90 days
Study: NCT00510484
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02838472
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
Study: NCT00351936
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02081001
Drug: Novo Nordisk GlucaGen®
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
Study: NCT02081001
Drug: G-Pump™ (glucagon infusion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
Study: NCT01343966
Drug: MABT5102A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating subcutaneous injection
Study: NCT01343966
Drug: MABT5102A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating intravenous infusion
Study: NCT01343966
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating subcutaneous injection
Study: NCT01343966
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating intravenous infusion